Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients
Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients
The purpose of the study is to investigate the effects of smart phone app on the secondary
 prevention for patients with coronary heart disease post percutaneous coronary intervention.
The secondary prevention for patients with coronary heart disease post percutaneous coronary
 intervention (PCI) proved associated with a significant reduction in mortality rates and
 improvement in quality of life. For the limitation of socio-economic conditions, not all
 patients post PCI are in a position to receive continuous standardized secondary prevention
 management. Therefore a smart phone app for secondary prevention management post PCI will be
 installed on patients' smart phones in order to investigate its effects on risk factors
 control, medication compliance, as well as quality of life and adverse cardiac events in the
 next six months post discharge. Participants allocated to the control group will receive a
 booklet with general advice on secondary prevention of coronary heart disease. Patients in
 app group and control group will be interviewed by telephone at the 2nd week and the 3rd
 month, and at the 1st month and 6th month they will return our hospital for face to face
 follow-up and to compliance and medication adjustment, assessment of life quality, risk
 factors control and medication adherence.
Inclusion Criteria:

 -  First diagnosis of coronary heart disease and received a PCI treatment.

 -  Age 18-65 years.

 -  Able and willing to provide written informed consent.

 Exclusion Criteria:

 -  Speech communication barriers.

 -  Patients with a clear history of allergies to anti-platelet drugs.

 -  Patients with a clear history of allergies to anti-platelet ᵦ-blockers.

 -  Patients with a clear history of allergies to statin drugs.

 -  Patients with a clear history of allergies to antihypertensive drugs.

 -  Patients with a clear history of allergies to antidiabetic drugs.

 -  Patients with serious heart failure(better than NYHA class II).

 -  Patients with cerebral infarction or cerebral hemorrhage.

 -  Patients with liver dysfunction (AST and ALT> 2 times that of the reference value).

 -  Patients with kidney dysfunction (creatinine clearance rate< 60ml/min).